$178.69
2.16% day before yesterday
Nasdaq, Jan 02, 10:01 pm CET
ISIN
US05464T1043
Symbol
AXSM

Axsome Therapeutics, Inc. Stock price

$178.69
+36.60 25.76% 1M
+74.78 71.97% 6M
-3.95 2.16% YTD
+91.37 104.64% 1Y
+101.56 131.67% 3Y
+97.25 119.41% 5Y
+166.50 1,365.87% 10Y
+169.95 1,944.51% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-3.95 2.16%
ISIN
US05464T1043
Symbol
AXSM
Industry

New AI Insights on Axsome Therapeutics, Inc. Insights AI Insights on Axsome Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.0b
Enterprise Value
$8.9b
Net debt
positive
Cash
$325.3m
Shares outstanding
50.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.1 | 14.0
EV/Sales
15.8 | 13.8
EV/FCF
negative
P/B
121.7
Financial Health
Equity Ratio
10.0%
Return on Equity
-503.5%
ROCE
-69.7%
ROIC
-76.6%
Debt/Equity
2.6
Financials (TTM | estimate)
Revenue
$561.3m | $641.8m
EBITDA
$-208.9m | $-160.3m
EBIT
$-215.3m | $-151.8m
Net Income
$-229.0m | $-186.4m
Free Cash Flow
$-101.4m
Growth (TTM | estimate)
Revenue
65.8% | 66.4%
EBITDA
30.4% | 41.6%
EBIT
29.8% | 46.0%
Net Income
26.4% | 35.1%
Free Cash Flow
23.5%
Margin (TTM | estimate)
Gross
91.9%
EBITDA
-37.2% | -25.0%
EBIT
-38.4%
Net
-40.8% | -29.0%
Free Cash Flow
-18.1%
More
EPS
$-4.6
FCF per Share
$-2.0
Short interest
6.7%
Employees
683
Rev per Employee
$560.0k
Show more

Is Axsome Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Axsome Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Axsome Therapeutics, Inc. forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Axsome Therapeutics, Inc. forecast:

Buy
96%
Hold
4%

Financial data from Axsome Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
561 561
66% 66%
100%
- Direct Costs 46 46
52% 52%
8%
516 516
67% 67%
92%
- Selling and Administrative Expenses 516 516
34% 34%
92%
- Research and Development Expense 189 189
16% 16%
34%
-209 -209
30% 30%
-37%
- Depreciation and Amortization 6.38 6.38
0% 0%
1%
EBIT (Operating Income) EBIT -215 -215
30% 30%
-38%
Net Profit -229 -229
26% 26%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Axsome Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Axsome Therapeutics, Inc. Stock News

Positive
Investors Business Daily
3 days ago
Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.
Positive
The Motley Fool
3 days ago
Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD).
Positive
Schaeffers Research
3 days ago
Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- its Alzheimer's disease agitation drug.
More Axsome Therapeutics, Inc. News

Company Profile

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Head office United States
CEO Herriott Tabuteau
Employees 683
Founded 2012
Website www.axsome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today